Johnson & Johnson has announced the first results of a Phase 3 study of Tremfya (guselkumab) in the treatment of moderately to severely active ulcerative colitis.

The study showed that 50% of patients receiving Tremfya 200 mg every four weeks and 45.2% of patients receiving 100 mg every eight weeks achieved clinical remission at week 44, compared with 18.9% for placebo.

Moreover, 67% and 71% of patients in clinical remission also achieved endoscopic remission.

Both dosages of Tremfya also met all nine primary secondary endpoints, with significant improvements over placebo.
These results suggest that Tremfya could offer a promising new therapeutic option for ulcerative colitis patients.

Copyright (c) 2024 CercleFinance.com. All rights reserved.